Blog
RSS FeedPosted by Michael Wonder on 17 Jul 2019
Knight Therapeutics announces Health Canada has approved Nerlynx for early-stage breast cancer
16 July 2019 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) for the extended adjuvant treatment of ...
Posted by Michael Wonder on 11 Jul 2019
Health Canada approves Pomalyst-based triplet combination for patients with multiple myeloma
10 July 2019 - Pomalyst in combination with bortezomib and dexamethasone, provides a new medication option for patients living with multiple ...
Posted by Michael Wonder on 27 Jun 2019
Knight announces filing of new drug submission for Ibsrela in Canada
26 June 2019 - Knight Therapeutics announced today that Knight's new drug submission for Ibsrela (tenapanor) has been accepted for ...
Posted by Michael Wonder on 12 Jun 2019
Sask. Cancer Agency started chemotherapy drug trial without required Health Canada approval
11 June 2019 - Agency says it 'proactively' paused trial 5 months after it started. ...
Posted by Michael Wonder on 30 May 2019
Health Canada approves Tecentriq (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer
29 May 2019 - Data show this new option can help some patients with metastatic non-small cell lung cancer live significantly ...
Posted by Michael Wonder on 09 May 2019
First and only PARP inhibitor, Lynparza (olaparib) approved as a first-line maintenance therapy treatment in BRCA mutated advanced ovarian cancer
8 May 2019 - AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 70% compared to ...
Posted by Michael Wonder on 04 May 2019
Seattle Genetics announces progress in expanding Adcentis (brentuximab vedotin) indications in Canada
3 May 2019 - Health Canada approves Adcetris in combination with AVD chemotherapy for the treatment of previously untreated Hodgkin's lymphoma ...
Posted by Michael Wonder on 12 Apr 2019
Health Canada issues Notice of Compliance with Conditions for Libtayo (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinom
11 April 2019 - Cutaneous squamous cell carcinoma is the second most common skin cancer in Canada. ...
Posted by Michael Wonder on 09 Apr 2019
Health Canada approves new drug to treat metastatic breast cancer through international and domestic joint reviews
9 April 2019 - Canadians want improved access to the most recent and innovative treatment options for themselves and their ...
Posted by Michael Wonder on 07 Apr 2019
Supporting greater availability of lower cost generic drugs for Canadians
4 April 2019 - Canadians want improved access to a wider range of safe and affordable medications. ...
Posted by Michael Wonder on 19 Mar 2019
New treatment option now available in Canada for newly diagnosed patients with advanced lung cancer
18 March 2019 - Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy reduced the risk of death by half compared ...
Posted by Michael Wonder on 11 Mar 2019
Imbruvica (ibrutinib) combination regimen to treat Waldenström's macroglobulinemia approved through Health Canada priority review
8 March 2019 - Imbruvica plus rituximab showed significant improvement in progression-free survival versus rituximab monotherapy in Waldenström's macroglobulinemia, a ...
Posted by Michael Wonder on 20 Feb 2019
Gilead receives approval in Canada for Yescarta (axicabtagene ciloleucel) CAR T therapy for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
19 February 2019 - Yescarta is a chimeric antigen receptor T-cell therapy that is custom-made for each patient from his or ...
Posted by Michael Wonder on 12 Feb 2019
Health Canada issues Notice of Compliance with Conditions for Idhifa the first oral targeted therapy for adult patients with relapsed or refractory acute myeloid leukaemia and an IDH2 mutation
11 February 2019 - Conditional approval validates Idhifa as the first and only oral, targeted inhibitor of IDH2. ...
Posted by Michael Wonder on 08 Feb 2019
Advanced Accelerator Applications announces Health Canada approval for Lutathera, a treatment for gastro-enteropancreatic neuroendocrine tumours
7 February 2019 - First ever approved peptide receptor radionuclide therapy in Canada. ...